Literature DB >> 16841136

Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire.

E Losina1, X Anglaret, Y Yazdanpanah, B Wang, S Toure, G R Seage, T N'Dri-Yoman, R P Walensky, N Dakoury-Dogbo, S J Goldie, E Messou, M C Weinstein, S Deuffic-Burban, R Salamon, K A Freedberg.   

Abstract

OBJECTIVE: To estimate incidence rates of opportunistic diseases (ODs) and mortality for patients with and without a history of OD among HIV-infected patients in Côte d'Ivoire.
METHODS: Using incidence density analysis, we estimated rates of ODs and chronic mortality by CD4 count in patients in a cotrimoxazole prophylaxis trial in Abidjan before the highly active antiretroviral therapy (HAART) era. Chronic mortality was defined as death without a history of OD or death more than 30 days after an OD diagnosis. We used Poisson's regression to examine the effect of OD history on chronic mortality after adjusting for age, gender, and current CD4 count.
RESULTS: Two hundred and seventy patients (40% male, mean age 33 years, median baseline CD4 count 261 cells/microl) were followed up for a median of 9.5 months. Bacterial infections and tuberculosis were the most common severe ODs. Of 47 patients who died, 9 (19%) died within 30 days of an OD, 26 (55%) died more than 30 days after an OD, and 12 (26%) died with no OD history. The chronic mortality rate was 31.0/100 person-years for those with an OD history, and 11.1/100 person-years for those with no OD history (rate ratio (RR) 2.81, 95% confidence interval (CI): 1.43 - 5.54). Multivariate analysis revealed that OD history remained an independent predictor of mortality (RR 2.15, 95% CI: 1.07 - 4.33) after adjusting for CD4 count, age and gender.
CONCLUSIONS: Before the HAART era, a history of OD was associated with increased chronic HIV mortality in Côte d'Ivoire, even after adjusting for CD4 count. These results provide further evidence supporting OD prophylaxis in HIV-infected patients.

Entities:  

Mesh:

Year:  2006        PMID: 16841136

Source DB:  PubMed          Journal:  S Afr Med J


  11 in total

1.  HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005.

Authors:  Elena Losina; Peter Figueroa; Jacqueline Duncan; Nomita Divi; Lindsey L Wolf; Lisa R Hirschhorn; Minnette Robertson; Kevin Harvey; Sheldon Whorms; Kenneth A Freedberg; Yitades Gebre
Journal:  Int J Infect Dis       Date:  2007-08-13       Impact factor: 3.623

2.  Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Authors:  Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

3.  Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.

Authors:  Sylvie Deuffic-Burban; Elena Losina; Bingxia Wang; Delphine Gabillard; Eugène Messou; Nomita Divi; Kenneth A Freedberg; Xavier Anglaret; Yazdan Yazdanpanah
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 8.082

Review 4.  Human immunodeficiency disease: how should it affect surgical decision making?

Authors:  T E Madiba; D J J Muckart; S R Thomson
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

5.  Colorectal cancer screening in human immunodeficiency virus population: Are they at average risk?

Authors:  Suresh Kumar Nayudu; Bhavna Balar
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

6.  Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Authors:  Kenneth A Freedberg; Nagalingeswaran Kumarasamy; Elena Losina; Anitha J Cecelia; Callie A Scott; Nomita Divi; Timothy P Flanigan; Zhigang Lu; Milton C Weinstein; Bingxia Wang; Aylur K Ganesh; Melissa A Bender; Kenneth H Mayer; Rochelle P Walensky
Journal:  AIDS       Date:  2007-07       Impact factor: 4.177

7.  Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.

Authors:  Melissa A Bender; Nagalingeswaran Kumarasamy; Kenneth H Mayer; Bingxia Wang; Rochelle P Walensky; Timothy Flanigan; Bruce R Schackman; Callie A Scott; Zhigang Lu; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Assessing the performance of a computer-based policy model of HIV and AIDS.

Authors:  Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

9.  Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Authors:  Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

10.  The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Marilyn G Tyler; Leann Schoeman; Delawir Kahn; Anwar S Mall
Journal:  Virol J       Date:  2008-05-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.